Reviewing Advaxis (ADXS) and Its Peers
Advaxis (NASDAQ: ADXS) is one of 190 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its rivals? We will compare Advaxis to related businesses based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.
Insider and Institutional Ownership
44.1% of Advaxis shares are owned by institutional investors. Comparatively, 45.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 7.2% of Advaxis shares are owned by insiders. Comparatively, 14.6% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares Advaxis and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Advaxis||$3.99 million||-$73.55 million||-1.33|
|Advaxis Competitors||$215.30 million||-$39.30 million||-64.17|
Advaxis’ rivals have higher revenue and earnings than Advaxis. Advaxis is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Advaxis has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Advaxis’ rivals have a beta of 1.54, indicating that their average stock price is 54% more volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Advaxis and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Advaxis presently has a consensus target price of $21.00, indicating a potential upside of 590.79%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.74%. Given Advaxis’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Advaxis is more favorable than its rivals.
This table compares Advaxis and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Advaxis Company Profile
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.